1. Medtech Insight
  2. >>Minute Insights

Minute Insight: Exai, Freenome Announce Major Financings To Advance Early Cancer Detection

 
• By Reed Miller

Freenome, developer of a blood test for early detection of colorectal cancer, announced a $300m series D funding. Exai Bio secured a $67.5m series A financing to accelerate development of its non-invasive, RNA-based liquid biopsy platform for early cancer detection.

Minute Insight

Two Bay Area cancer diagnostics companies announced noteworthy funding rounds this week.

Freenome announced a series D funding of $300m, led by Perceptive Advisors and RA Capital Management, on 7 December. Since...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Minute Insights

More from Medtech Insight

GE HealthCare Halves 2025 Tariff EPS Hit As Global Supply Chain Realigns

 
• By Shubham Singh

For the third quarter of 2025, GE HealthCare projects year-over-year organic revenue growth in the range of 2%-3%. However, adjusted EPS is expected to decline in the high single digits year-over-year, reflecting the ongoing effect of tariff costs.

Roberts’ Departure At NICE Sparks Hunt For New CEO

 
• By Ashley Yeo

Healthtechs are reflecting on the resignation of Sam Roberts as chief executive of NICE and how medtech assessment program changes underway at the England and Wales HTA body might be impacted.

Inspection Readiness 101: Be Prepared To Avoid Common Pitfalls When The FDA Comes Knocking

 
• By Brian Bossetta

A panel of regulatory pros offered stakeholders tips for avoiding FDA citations after facility inspections. The July 29 webinar, hosted by ProPharma and Hyman Phelps and McNamara, follows the agency’s May announcement that it plans to up random foreign inspections.